Biolegend, 100725, Pacific Blue™ anti-mouse CD8a Antibody, 100μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application. * Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Chen Y, et al. 2020. Virol Sin. . PubMed Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed Dhalech AH, et al. 2022. J Virol. 96:e0123222. PubMed Ke F, et al. 2023. Elife. 12:. PubMed Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed Ramos SA, et al. 2022. J Allergy Clin Immunol. 149:767. PubMed Chae CS, et al. 2022. Cancer Discov. 12:1904. PubMed Simpson AP, et al. 2022. Cell Rep. 40:111099. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Ali LR, et al. 2023. J Exp Med. 220: . PubMed Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed Novaj A, et al. 2023. Int J Mol Sci. 24: . PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Kodali S, et al. 2022. J Immunol. 208:1085. PubMed Fueyo-González F, et al. 2022. Immunity. 55:459. PubMed Olson SW, et al. 2022. Mol Cell. 82:1708. PubMed McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed Tan L, et al. 2022. Aging Dis. 13:1562. PubMed Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed Schneider C, et al. 2018. Cell. 174:271. PubMed Page N, et al. 2018. Immunity. 48:937. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Zhu W, et al. 2021. Onco Targets Ther. 14:2149. PubMed Fan L, et al. 2021. Cancers (Basel). 13:. PubMed Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed Molofsky A, et al. 2013. J Exp Med. 210:535. PubMed Li Y, et al. 2020. Cell Rep. 30:1753. PubMed Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed Gu M, et al. 2021. Nat Immunol. 22:193. PubMed Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed Saito S, et al. 2020. Nutrients. 12:. PubMed Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed Price J, et al. 2015. Diabetes. 64: 3521 - 3531. PubMed Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed Geiger R, et al. 2016. Cell. 167:829-842. PubMed Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed Li H, et al. 2022. Theranostics. 12:6422. PubMed JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed Atkinson S, et al. 2016. Dis Model Mech. 9: 427-440. PubMed Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed Jasti S, et al. 2017. Biol Reprod. 96:134. PubMed Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed Melissa M Remy et al. 2017. Cell host & microbe. 22(3):354-365 . PubMed Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed Kälin S et al. 2017. Cell metabolism. 26(3):475-492 . PubMed López MJ, et al. 2018. Invest Ophthalmol Vis Sci. 59:5671. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed De Ponte Conti B, et al. 2021. Elife. 10:. PubMed Chun N, et al. 2021. JCI Insight. 6:. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Mohebiany AN, et al. 2020. Cell Reports. 30(5):1585-1597.e6.. PubMed Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed Blanchard L, et al. 2022. STAR Protoc. 3:101444. PubMed Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed Engblom C, et al. 2017. Science. 358:6367. PubMed Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed Tian Q, et al. 2022. Front Mol Neurosci. 15:850904. PubMed Kwok T, et al. 2022. Front Aging. 3:838943. PubMed Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed Zhang Z, et al. 2020. Nature. 579:415. PubMed Wang X, et al. 2022. Elife. 11:. PubMed Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed Serr I, et al. 2016. Nat Commun. 7:10991. PubMed Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed Chen D, et al. 2021. JCI Insight. 6:. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed Wolf Y, et al. 2019. Cell. 179:219. PubMed Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID: AB_493426 (BioLegend Cat. No. 100728) AB_493425 (BioLegend Cat. No. 100725)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ